Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

The present disclosure provides systems, methods and apparatuses for inducing a desired biological response in an organism through the use of one or more repetitive signals from one or a series of LED lights designed to emit the signal with multiple pulsed components. Each component of the signal contains a one or more light color spectrum or wavelength that is within 50 nm of the peak absorption of a photon receptor of the organism corresponding to the desired biological response. Each component has a repetitive ON duration with an OFF duration and an intensity where the relationship between the ON duration and OFF duration of the first component and the second component induces the desired response in the organism through the stimulation or excitation of a molecule associated with a photoreceptor and the reset of the molecule.

This disclosure pertains to a system configured to control light exposure for circadian phase management and/or light deficient disorders of a subject. The system comprises a user interface, physiological sensors configured to generate output signals conveying physiological data of the subject, and a light control valve configured to block or reduce blue light ambient radiation reaching eyes of the subject. Processors are in communication with the user interface, the physiological sensors, the light control valve, and radiation generators. The processors cause the system to receive physiological goals of the subject, determine a light control plan based on the physiological goals, the physiological data, environmental data, and time data. The system operates the light control valve to block or reduce blue light ambient radiation based on the light control plan, and generate, using the one or more radiation generators, therapeutic light radiation based on the light control plan.

A platinum(IV) complex has the structure of Formula I.

##STR00001##

where X, X′, Y, Y′, and Z are each independently an electron donor ligand, R.sub.1˜R.sub.5 are each independently a functional group, L is the linker unit, and n is selected from the group of 0, a positive charge, and a negative charge. Various methods contain steps for manufacturing the platinum(IV) complex, for treating cancer, a tumor, or an infection in a subject with the platinum(IV) complex. A pharmaceutical composition contains the platinum(IV) complex.

In one aspect, embodiments relate to a system for preventative dental laser treatment that ensures even irradiation of a laser beam. The system includes, a laser arrangement configured to generate the laser beam. The laser beam has one or more of a super-Gaussian energy profile and a transverse ring mode. The system also includes a focus optic. The focus optic is configured to converge the laser beam with a numerical aperture of 0.1 or less to a focal region. The system also includes a hand piece configured to direct the laser beam at a surface of a dental hard tissue. The system additionally includes a controller. The controller is configured to control one or more parameters of the laser source, such that a portion of the surface of the dental hard tissue is heated to a temperature in a range between 400° Celsius and 1300° Celsius.

Devices, systems, and methods can be used to deliver photobiomodulation therapy (PBMT) to the GI tract. For example, this document describes battery-enabled LED light source devices that can be deployed through or over an endoscope and anchored directly to the GI tract. Significant systemic effects can be produced by PBMT with application to one part of the body promoting beneficial anti-inflammatory and metabolic benefits in other remote sites promoted by enhanced mitochondrial function and mitokine signaling.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., skin cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma or basal cell carcinoma.

A feedback energy-release system and operation method thereof are provided, adapted to provide an energy parameter to an energy-release apparatus for performing a plurality of energy-release operations on a target skin. A feature capturing device captures tissue feature data of the target skin, wherein the tissue feature data captured before and after each energy-release operation are a first and a second tissue feature data, respectively. A control device compares the second tissue feature data with a plurality of reference tissue feature data to obtain at least one suggested energy parameter, determines grades of the tissue feature data of the current energy-release operation and records a grade distribution of the tissue feature data. The control device generates the energy parameter of the next energy-release operation according to a difference between the first and second tissue feature data, the at least one suggested energy parameter and the grade distribution.

A feedback energy-release system and operation method thereof are provided, adapted to provide an energy parameter to an energy-release apparatus for performing a plurality of energy-release operations on a target skin. A feature capturing device captures tissue feature data of the target skin, wherein the tissue feature data captured before and after each energy-release operation are a first and a second tissue feature data, respectively. A control device compares the second tissue feature data with a plurality of reference tissue feature data to obtain at least one suggested energy parameter, determines grades of the tissue feature data of the current energy-release operation and records a grade distribution of the tissue feature data. The control device generates the energy parameter of the next energy-release operation according to a difference between the first and second tissue feature data, the at least one suggested energy parameter and the grade distribution.